https://www.pharmaradar360.com/article/apifix-46d2d81a536c4a0fPharma Surgeen2026-06-23T16:28:37.000ZApiFix®https://www.pharmaradar360.com/article/u-s-global-health-legislation-tracker-ec916851cb08fd5cPharma Surgeen2026-06-23T16:27:00.000ZU.S. Global Health Legislation Trackerhttps://www.pharmaradar360.com/article/certara-launches-bio-venture-catalyst-for-emerging-biotechs-to-de-risk-investmen-285e38daf51b4e87Pharma Surgeen2026-06-23T16:23:54.000ZCertara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Developmenthttps://www.pharmaradar360.com/article/integrating-endogenous-ligand-competition-into-a-mechanistic-whole-body-pbpk-mod-dc624ab93f1623c5Pharma Surgeen2026-06-23T16:01:47.000ZIntegrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodieshttps://www.pharmaradar360.com/article/uld-container-vs-non-uld-container-what-is-the-difference-1d6f91f02d1e259fPharma Surgeen2026-06-23T15:40:56.000ZULD Container vs.Non-ULD Container: What Is the Difference?https://www.pharmaradar360.com/article/63-runs-and-no-convergence-when-rsnlme-succeeded-where-others-couldn-t-e3c26a63c947bf74Pharma Surgeen2026-06-23T15:40:06.000Z63 Runs and No Convergence: When RsNLME Succeeded Where Others Couldn’thttps://www.pharmaradar360.com/article/witness-carolina-s-role-in-the-revolutionary-war-950bffcb032a61c8Pharma Surgeen2026-06-23T15:31:34.000Z‘Witness’ Carolina’s role in the Revolutionary Warhttps://www.pharmaradar360.com/article/ns-035-ad3fe6ba9e021a37Pharma Surgeen2026-06-23T15:30:00.000Z福山型先天性筋ジストロフィー治療剤「NS-035」希少疾病用医薬品指定のお知らせhttps://www.pharmaradar360.com/article/64eecea013c8434fPharma Surgeen2026-06-23T15:30:00.000Zボストン小児病院との共同研究契約締結のお知らせhttps://www.pharmaradar360.com/article/the-first-90-days-after-fda-clearance-greenlight-guru-4dbaf47997c9ea77Pharma Surgeen2026-06-23T15:26:40.000ZThe first 90 days after FDA clearance | Greenlight Guruhttps://www.pharmaradar360.com/article/field-safety-notices-15-to-19-june-2026-0dae56725b81dbb3Pharma Surgeen2026-06-23T15:23:17.000ZField Safety Notices: 15 to 19 June 2026https://www.pharmaradar360.com/article/the-tea-in-your-kombucha-changes-more-than-just-the-taste-922ed75d23508a0bPharma Surgeen2026-06-23T15:06:00.000ZThe tea in your kombucha changes more than just the tastehttps://www.pharmaradar360.com/article/la-unlp-realizara-una-jornada-de-asesoramiento-previsional-0d92d5ca55059efaPharma Surgeen2026-06-23T15:05:43.000ZLa UNLP realizará una jornada de asesoramiento previsionalhttps://www.pharmaradar360.com/article/nueva-entrega-de-computadoras-a-estudiantes-de-la-unlp-f5fac08c2fd2a85dPharma Surgeen2026-06-23T15:05:06.000ZNueva entrega de computadoras a estudiantes de la UNLPhttps://www.pharmaradar360.com/article/huella-hidrica-c1ca10512b51cc09Pharma Surgeen2026-06-23T14:59:24.000ZHuella hídricahttps://www.pharmaradar360.com/article/palabras-del-presidente-fernando-tauber-en-el-inicio-de-su-gestion-2026-2030-9a9dbd51e9b55d1dPharma Surgeen2026-06-23T14:57:40.000ZPalabras del Presidente Fernando Tauber en el inicio de su gestión 2026-2030https://www.pharmaradar360.com/article/pittsburgh-business-leader-to-head-2026-heart-walk-and-citywide-push-for-cpr-rea-916f5884ac4bd6a2Pharma Surgeen2026-06-23T14:57:00.000ZPittsburgh business leader to head 2026 Heart Walk and citywide push for CPR readinesshttps://www.pharmaradar360.com/article/jornada-de-buen-trato-hacia-las-personas-mayores-db8a1513d3e95feaPharma Surgeen2026-06-23T14:55:25.000ZJornada de buen trato hacia las personas mayoreshttps://www.pharmaradar360.com/article/cpa-da-ufrj-define-coordenacao-e-planeja-proximos-passos-da-avaliacao-institucio-8f80df7fa0acbbefPharma Surgeen2026-06-23T14:35:00.000ZCPA da UFRJ define coordenação e planeja próximos passos da avaliação institucionalhttps://www.pharmaradar360.com/article/scientists-finally-solved-how-h5n1-bird-flu-hid-in-dairy-cows-0bc6afc35a6a5a50Pharma Surgeen2026-06-23T14:31:51.000ZScientists finally solved how H5N1 bird flu hid in dairy cowshttps://www.pharmaradar360.com/article/performance-of-the-techcyte-ai-based-image-analysis-system-for-coproparasitologi-f52fee6ab651e077Pharma Surgeen2026-06-23T14:23:29.000ZPerformance of the Techcyte AI-based image analysis system for coproparasitological diagnosis in clinical stool specimens: a retrospective evaluation studyhttps://www.pharmaradar360.com/article/the-fortin-family-foundation-makes-extraordinary-5-million-gift-to-the-campaign-ca842f128560900bPharma Surgeen2026-06-23T14:23:07.000ZThe Fortin Family Foundation Makes Extraordinary $5 Million Gift to the Campaign for St. Vincent Regional Hospitalhttps://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7Pharma Surgeen2026-06-23T14:17:25.000ZMedicines eligible for Northern Ireland MHRA Authorised Routehttps://www.pharmaradar360.com/article/las-invasiones-inglesas-y-el-nacimiento-de-una-identidad-nacional-5ff061e1aeaee733Pharma Surgeen2026-06-23T14:08:13.000ZLas Invasiones Inglesas y el nacimiento de una identidad nacionalhttps://www.pharmaradar360.com/article/homenaje-a-la-bandera-en-los-jardines-del-rectorado-df0d43f386ffd1cbPharma Surgeen2026-06-23T13:59:59.000ZHomenaje a la Bandera en los jardines del Rectoradohttps://www.pharmaradar360.com/article/application-of-io-simulator-in-immuno-oncology-combination-therapy-a-small-cell-3d00c4089200d552Pharma Surgeen2026-06-23T13:58:37.000ZApplication of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Studyhttps://www.pharmaradar360.com/article/breve-elogio-sobre-la-libertad-academica-b735fca67b2a4d6cPharma Surgeen2026-06-23T13:57:55.000ZBreve elogio sobre la libertad académicahttps://www.pharmaradar360.com/article/the-medical-frailty-exemption-from-medicaid-work-requirements-key-takeaways-from-60411ed4c27b4044Pharma Surgeen2026-06-23T13:55:48.000ZThe Medical Frailty Exemption from Medicaid Work Requirements: Key Takeaways from the CMS Interim Final Rulehttps://www.pharmaradar360.com/article/fourteen-oxford-academics-awarded-major-european-research-council-advanced-grant-6f61084b1c8139d5Pharma Surgeen2026-06-23T13:53:43.000ZFourteen Oxford academics awarded major European Research Council Advanced Grantshttps://www.pharmaradar360.com/article/strategic-health-purchasing-as-an-enabler-of-health-systems-resilience-in-fragil-87d57da5ee7b76eePharma Surgeen2026-06-23T13:47:24.000ZStrategic Health Purchasing as an Enabler of Health Systems Resilience in Fragile States: Evidence from South Sudanhttps://www.pharmaradar360.com/article/fortitude-and-heartsciences-nasdaq-hscs-announce-business-combination-aiming-to-3980f5efadd81bc3Pharma Surgeen2026-06-23T13:44:56.000ZFortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Marketshttps://www.pharmaradar360.com/article/mas-sustentable-la-unlp-redujo-un-12-su-huella-de-carbono-dc3615e7287227ecPharma Surgeen2026-06-23T13:44:30.000ZMás sustentable: la UNLP redujo un 12% su huella de carbonohttps://www.pharmaradar360.com/article/la-unlp-reunio-a-mas-de-40-equipos-editoriales-en-el-encuentro-de-revistas-cient-ac9de3f9fd2728c9Pharma Surgeen2026-06-23T13:43:52.000ZLa UNLP reunió a más de 40 equipos editoriales en el Encuentro de Revistas Científicashttps://www.pharmaradar360.com/article/jornada-por-el-dia-mundial-del-ambiente-accion-por-el-clima-del-saber-al-hacer-37181135bcdc5ec7Pharma Surgeen2026-06-23T13:43:10.000ZJornada por el día mundial del ambiente: acción por el clima, del saber al hacerhttps://www.pharmaradar360.com/article/la-unlp-realizo-una-nueva-colecta-de-sangre-y-jornada-integral-de-salud-fe045f3184c5898bPharma Surgeen2026-06-23T13:42:30.000ZLa UNLP realizó una nueva colecta de sangre y jornada integral de saludhttps://www.pharmaradar360.com/article/agenda-conjunta-con-la-union-de-parlamentarios-sudamericanos-764a255dfc8902b0Pharma Surgeen2026-06-23T13:38:16.000ZAgenda conjunta con la Unión de Parlamentarios Sudamericanoshttps://www.pharmaradar360.com/article/tauber-recorrio-las-obras-del-edificio-anexo-de-derecho-80e838733cabaa73Pharma Surgeen2026-06-23T13:36:36.000ZTauber recorrió las obras del edificio Anexo de Derechohttps://www.pharmaradar360.com/article/jornada-por-una-universidad-libre-de-humo-y-nicotina-5e6696bbbe94980fPharma Surgeen2026-06-23T13:34:02.000ZJornada por una Universidad libre de humo y nicotinahttps://www.pharmaradar360.com/article/la-unlp-y-china-afianzan-lazos-de-cooperacion-con-la-inauguracion-de-un-nuevo-ce-b656851b1493f8dcPharma Surgeen2026-06-23T13:33:25.000ZLa UNLP y China afianzan lazos de cooperación con la inauguración de un nuevo centro culturalhttps://www.pharmaradar360.com/article/revolutionary-copd-injection-given-to-patients-for-first-time-261b7d9eb2567bdfPharma Surgeen2026-06-23T13:24:12.000ZRevolutionary COPD injection given to patients for first timehttps://www.pharmaradar360.com/article/what-makes-mri-the-perfect-fit-for-interventional-workflows-these-pioneers-expla-c83c049dc6a0954bPharma Surgeen2026-06-23T13:17:45.000ZWhat Makes MRI the Perfect Fit for Interventional Workflows? These Pioneers Explain.https://www.pharmaradar360.com/article/de-risk-adenoviral-vector-development-with-an-adaptive-platform-73e51507005b33eePharma Surgeen2026-06-23T13:10:00.000ZDe-Risk Adenoviral Vector Development with an Adaptive Platformhttps://www.pharmaradar360.com/article/sk-pharmteco-announces-skyvectm-a-unified-high-yield-viral-vector-platform-desig-fe7647be36171d83Pharma Surgeen2026-06-23T13:05:00.000ZSK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedsidehttps://www.pharmaradar360.com/article/mechanistic-modelling-of-crs-in-t-cell-engagers-an-application-for-blinatumomab-310fc062f187c580Pharma Surgeen2026-06-23T12:59:15.000ZMechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomabhttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-29776fbc92997ea0Pharma Surgeen2026-06-23T12:59:11.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: Related Resourceshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-da141fb5d19965f4Pharma Surgeen2026-06-23T12:59:06.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: 1115-waivershttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-38463bac8179533dPharma Surgeen2026-06-23T12:59:01.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Implementation Questionshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-6639d664866d5eddPharma Surgeen2026-06-23T12:58:56.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirementshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-f066079fc0240f7ePharma Surgeen2026-06-23T12:58:10.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Data and Policieshttps://www.pharmaradar360.com/article/easygrid-towards-better-automation-in-cryo-electron-microscopy-3e5dc74d617e422dPharma Surgeen2026-06-23T12:39:38.000ZEasyGrid: towards better automation in cryo-electron microscopyhttps://www.pharmaradar360.com/article/basic-science-research-retreat-aims-at-collaboration-2be2816482c0c999Pharma Surgeen2026-06-23T12:19:57.000ZBasic science research retreat aims at collaborationhttps://www.pharmaradar360.com/article/dr-erickson-to-take-new-continuing-education-role-f8e68238ad39ff4dPharma Surgeen2026-06-23T12:18:56.000ZDr. Erickson to take new continuing education rolehttps://www.pharmaradar360.com/article/regan-taylor-md-named-director-of-phase-2-7fa1c7f864285b93Pharma Surgeen2026-06-23T12:17:40.000ZRegan Taylor, MD, named director of Phase 2https://www.pharmaradar360.com/article/medical-research-highlights-june-2026-ee724de04515f5f0Pharma Surgeen2026-06-23T12:15:30.000ZMedical research highlights, June 2026https://www.pharmaradar360.com/article/mello-finishes-term-as-aamc-steering-committee-chair-7c68909bd57d0202Pharma Surgeen2026-06-23T12:14:05.000ZMello finishes term as AAMC steering committee chairhttps://www.pharmaradar360.com/article/retirement-reception-july-28-for-shantaram-joshi-phd-a85f739d9b73b238Pharma Surgeen2026-06-23T12:12:52.000ZRetirement reception July 28 for Shantaram Joshi, PhDhttps://www.pharmaradar360.com/article/allergy-and-immunology-fellowship-program-nets-acaai-grant-6806eeffbaea87cePharma Surgeen2026-06-23T12:11:33.000ZAllergy and immunology fellowship program nets ACAAI granthttps://www.pharmaradar360.com/article/dean-s-message-applause-thanks-and-holiday-best-wishes-2e9f1f6db09b3a0ePharma Surgeen2026-06-23T12:10:27.000ZDean’s message: Applause, thanks and holiday best wisheshttps://www.pharmaradar360.com/article/new-brain-study-reveals-speech-learning-works-differently-than-we-thought-3b2266764e9f6a6dPharma Surgeen2026-06-23T12:06:13.000ZNew brain study reveals speech learning works differently than we thoughthttps://www.pharmaradar360.com/article/rector-and-dean-of-unsw-canberra-visits-kyoto-university-c3aa348e327826aePharma Surgeen2026-06-23T12:00:00.000ZRector and Dean of UNSW Canberra visits Kyoto Universityhttps://www.pharmaradar360.com/article/hoffmann-ii-carbon-connecting-rod-f7e8d926ffd8e318Pharma Surgeen2026-06-23T12:00:00.000ZHoffmann® II Carbon Connecting Rodhttps://www.pharmaradar360.com/article/allergan-aesthetics-receives-approval-for-boey-trenibotulinumtoxine-in-canada-th-f5cf71c0df5d0e56Pharma Surgeen2026-06-23T12:00:00.000ZAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientshttps://www.pharmaradar360.com/article/withdrawn-cancer-accelerated-approvals-9d91fd407d4e65c0Pharma Surgeen2026-06-23T11:52:49.000ZWithdrawn | Cancer Accelerated Approvalshttps://www.pharmaradar360.com/article/university-athletes-set-to-shine-at-glasgow-2026-b4d60e6289c20addPharma Surgeen2026-06-23T11:44:12.000ZUniversity athletes set to shine at Glasgow 2026https://www.pharmaradar360.com/article/volantetm-steerable-guiding-sheath-now-available-in-us-f121ffe7b3f918a3Pharma Surgeen2026-06-23T11:43:23.000ZVolante™ Steerable Guiding Sheath now available in UShttps://www.pharmaradar360.com/article/high-quality-workshop-on-global-health-economics-in-low-and-middle-income-countr-4d4f46a0ffea2cb7Pharma Surgeen2026-06-23T11:40:00.000ZHigh quality workshop on Global Health Economics in low- and middle-income countrieshttps://www.pharmaradar360.com/article/rethinking-alzheimer-s-clinical-trials-to-include-atypical-forms-of-the-disease-a766d0ec456d1a33Pharma Surgeen2026-06-23T11:32:00.000ZRethinking Alzheimer’s clinical trials to include atypical forms of the diseasehttps://www.pharmaradar360.com/article/one-of-the-world-s-most-popular-weedkillers-may-be-fueling-deadly-superbugs-ae82ebc3cb1f9dbePharma Surgeen2026-06-23T11:31:51.000ZOne of the world’s most popular weedkillers may be fueling deadly superbugshttps://www.pharmaradar360.com/article/dating-fraudsters-gain-your-trust-first-then-your-money-1170b95d099e622dPharma Surgeen2026-06-23T11:05:36.000ZDating fraudsters gain your trust first, then your moneyhttps://www.pharmaradar360.com/article/uncommon-cancers-common-goals-overcoming-the-challenges-of-rare-cancer-research-34d442ed19f1eff1Pharma Surgeen2026-06-23T11:00:00.000ZUncommon Cancers, Common Goals: Overcoming the Challenges of Rare Cancer Researchhttps://www.pharmaradar360.com/article/tech-executive-named-chair-of-the-2026-long-island-heart-walk-e623497f6ffe4837Pharma Surgeen2026-06-23T11:00:00.000ZTech executive named chair of the 2026 Long Island Heart Walkhttps://www.pharmaradar360.com/article/how-ai-1-billion-and-a-transparent-fish-could-transform-neuroscience-ec0955807d747b86Pharma Surgeen2026-06-23T10:50:00.000ZHow AI, $1 billion, and a transparent fish could transform neurosciencehttps://www.pharmaradar360.com/article/bd-awarded-vizient-innovative-technology-contract-for-centrovena-onetm-insertion-dd54fa3453f44ac3Pharma Surgeen2026-06-23T10:50:00.000ZBD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion Systemhttps://www.pharmaradar360.com/article/two-erc-advanced-grants-awarded-to-researchers-at-the-university-of-freiburg-89b4206511fa6bf6Pharma Surgeen2026-06-23T10:49:36.000ZTwo ERC Advanced Grants awarded to researchers at the University of Freiburghttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-e53c9537c2a4e38cPharma Surgeen2026-06-23T10:42:49.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-416d964690a20061Pharma Surgeen2026-06-23T10:42:34.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/living-medicine-and-ai-designed-proteins-to-fight-lung-cancer-from-within-ed0942e26fe3e653Pharma Surgeen2026-06-23T10:35:27.000Z‘Living medicine’ and AI-designed proteins to fight lung cancer from withinhttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-2f4bce1535a99302Pharma Surgeen2026-06-23T10:15:23.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/polio-global-eradication-nac-and-environmental-surveillance-28a88d7a1d6b4d94Pharma Surgeen2026-06-23T10:11:44.000ZPolio: global eradication, NAC and environmental surveillancehttps://www.pharmaradar360.com/article/vaccines-europe-welcomes-new-leadership-team-5a91f36db169e78cPharma Surgeen2026-06-23T10:01:05.000ZVaccines Europe Welcomes New Leadership Teamhttps://www.pharmaradar360.com/article/12-50-cbe6322095440881Pharma Surgeen2026-06-23T09:44:33.000Zฉลองครบรอบ 12 ปี อมรินทร์ทีวี และ 50 ปี อมรินทร์กรุ๊ป จัดตั้ง “กองทุนสื่อสานธรรม”https://www.pharmaradar360.com/article/how-lung-cancer-screening-can-save-lives-public-facing-videos-from-the-solace-pr-966ed60ce51d1430Pharma Surgeen2026-06-23T09:24:00.000ZHow Lung Cancer Screening Can Save Lives – Public-facing videos from the SOLACE Projecthttps://www.pharmaradar360.com/article/006a9c520a03653ePharma Surgeen2026-06-23T09:21:19.000Zデュルバルマブ適正使用のお願い_胃癌（アストラゼネカ株式会社）https://www.pharmaradar360.com/article/is-ai-still-biased-7f532f5da849c563Pharma Surgeen2026-06-23T09:00:00.000ZIs AI (Still) Biased?https://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-maviret-glecaprevir-pibrentasvi-9c09ce9af9a04998Pharma Surgeen2026-06-23T09:00:00.000ZAbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infectionhttps://www.pharmaradar360.com/article/erc-advanced-grants-for-researchers-at-universitat-heidelberg-93328ec77e85e454Pharma Surgeen2026-06-23T08:59:34.000ZERC Advanced Grants for Researchers at Universität Heidelberghttps://www.pharmaradar360.com/article/strengthening-partnerships-with-patient-organizations-insights-and-opportunities-9c89c0ee6aecb5a9Pharma Surgeen2026-06-23T08:46:09.000ZStrengthening partnerships with patient organizations: insights and opportunities for progresshttps://www.pharmaradar360.com/article/rgx-121-regenxbio-bla-fda-3d6726130409a77dPharma Surgeen2026-06-23T08:45:00.000ZRGX-121：REGENXBIO社が迅速承認に向けた生物製剤承認申請（BLA）再提出についてFDAと合意https://www.pharmaradar360.com/article/22-juin-journee-nationale-de-reflexion-sur-le-don-d-organes-et-la-greffe-8e314a6584ff96e3Pharma Surgeen2026-06-23T08:44:57.000Z22 juin : journée nationale de réflexion sur le don d'organes et la greffehttps://www.pharmaradar360.com/article/dr-wouter-vaes-chief-science-officer-at-peregrion-b5d9355e183a4052Pharma Surgeen2026-06-23T08:10:57.000ZDr. Wouter Vaes - Chief Science Officer at Peregrionhttps://www.pharmaradar360.com/article/arvostettu-eu-n-miljoonarahoitus-viidelle-helsingin-yliopiston-tutkijalle-6ad47b842bb112f9Pharma Surgeen2026-06-23T08:05:14.000ZArvostettu EU:n miljoonarahoitus viidelle Helsingin yliopiston tutkijallehttps://www.pharmaradar360.com/article/ukri-launches-two-ai-research-labs-to-stay-ahead-in-global-race-3cee792585299a4bPharma Surgeen2026-06-23T08:00:34.000ZUKRI launches two AI research labs to stay ahead in global racehttps://www.pharmaradar360.com/article/fama-jallow-reaching-beyond-the-stars-to-reimagine-solutions-for-africa-8e005a58f2122bb1Pharma Surgeen2026-06-23T07:36:29.000ZFama Jallow: Reaching beyond the stars to reimagine solutions for Africahttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-februar-3b2232fe8c91f5e1Pharma Surgeen2026-06-23T07:26:06.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: February 2026https://www.pharmaradar360.com/article/die-tagesklinik-am-nct-heidelberg-wie-onkologische-pflege-ambulant-funktioniert-0a1f336559322860Pharma Surgeen2026-06-23T07:13:17.000ZDie Tagesklinik am NCT Heidelberg – Wie onkologische Pflege ambulant funktionierthttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-may-e370cce99107b990Pharma Surgeen2026-06-23T07:03:34.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: May 2026https://www.pharmaradar360.com/article/a-message-from-leadership-on-joint-accreditation-d61d71311e703424Pharma Surgeen2026-06-23T07:02:00.000ZA message from leadership on joint accreditationhttps://www.pharmaradar360.com/article/diagnosing-a-passion-unmc-s-high-school-alliance-00040c8d71868162Pharma Surgeen2026-06-23T07:00:00.000ZDiagnosing a passion: UNMC’s High School Alliancehttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-tr-05301d26b8674ac8Pharma Surgeen2026-06-23T07:00:00.000ZAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasishttps://www.pharmaradar360.com/article/leci-research-seminar-on-may-8th-on-educational-interventions-two-case-examples-576667014608842cPharma Surgeen2026-06-23T06:41:55.000ZLECI Research Seminar on May 8th: On educational interventions: two case examples and discussionhttps://www.pharmaradar360.com/article/flinders-business-school-launches-australia-s-first-mba-specialising-in-ai-strat-df4cfab52f936bf5Pharma Surgeen2026-06-23T06:21:25.000ZFlinders Business School launches Australia’s first MBA specialising in AI strategy and leadershiphttps://www.pharmaradar360.com/article/aimd-active-implants-scs-infinion-cx-lead-infinion-cx-c2ab1440d9c353ddPharma Surgeen2026-06-23T06:20:01.000ZΑνάκληση των αχρησιμοποίητων παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος κατηγορίας AIMD Active implants, SCS Infinion CX Lead (Κιτ απαγωγής Infinion CX)https://www.pharmaradar360.com/article/result-of-agm-14618f644432fb55Pharma Surgeen2026-06-23T06:07:07.000ZResult of AGMhttps://www.pharmaradar360.com/article/five-fully-funded-fellowships-in-health-and-sustainability-open-for-applications-f153e7004d5fff1cPharma Surgeen2026-06-23T05:54:42.000ZFive fully-funded fellowships in Health and Sustainability open for applicationshttps://www.pharmaradar360.com/article/minnesota-sugar-beet-growers-brace-for-the-possible-return-of-a-devastating-dise-7d23d1de8f7da252Pharma Surgeen2026-06-23T04:27:11.000ZMinnesota sugar beet growers brace for the possible return of a devastating diseasehttps://www.pharmaradar360.com/article/positive-psychology-aids-children-s-mental-health-92929e4d71f9770fPharma Surgeen2026-06-23T04:26:37.000ZPositive psychology aids children’s mental healthhttps://www.pharmaradar360.com/article/study-twin-cities-still-attractive-to-big-business-and-career-employees-but-conc-a95551a2031c4c1fPharma Surgeen2026-06-23T04:25:31.000ZStudy: Twin Cities still attractive to big business and career employees, but concerns emerginghttps://www.pharmaradar360.com/article/evonik-sells-hanau-pharmaceutical-ingredients-production-assets-to-prochem-6209a971c5dc25cbPharma Surgeen2026-06-23T03:12:22.000ZEvonik Sells Hanau Pharmaceutical Ingredients Production Assets To ProChemhttps://www.pharmaradar360.com/article/this-emerging-treatment-is-helping-people-avoid-knee-replacement-surgery-fcb47177d0ba499fPharma Surgeen2026-06-23T03:04:58.000ZThis emerging treatment is helping people avoid knee replacement surgeryhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-vabysmo-partial-change-approval-43fcf402c3af1283Pharma Surgeen2026-06-23T03:00:00.000Z[SHINSA]English Translation of Review Report: Vabysmo (Partial Change Approval)https://www.pharmaradar360.com/article/small-sleep-sacks-big-compliance-lessons-what-fda-s-happiest-baby-warning-letter-f58146f67dfb2307Pharma Surgeen2026-06-23T02:45:39.000ZSmall Sleep Sacks, Big Compliance Lessons: What FDA’s Happiest Baby Warning Letter Means for Device Manufacturershttps://www.pharmaradar360.com/article/biotech-chief-says-industry-in-better-place-after-fda-changes-bea29e624d847877Pharma Surgeen2026-06-23T02:14:00.000ZBiotech Chief Says Industry in ‘Better Place’ After FDA Changeshttps://www.pharmaradar360.com/article/scientists-say-most-people-need-more-protein-than-current-guidelines-suggest-6fbae02bb7c94c87Pharma Surgeen2026-06-23T01:44:42.000ZScientists say most people need more protein than current guidelines suggesthttps://www.pharmaradar360.com/article/innovent-pfizer-deal-makes-joint-development-commercialization-pillar-in-biotech-ddb634b0622e63edPharma Surgeen2026-06-23T01:22:00.000ZInnovent-Pfizer deal makes joint development, commercialization pillar in biotech global pushhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-66bc714f3c69417cPharma Surgeen2026-06-23T01:11:55.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-78d5a8bfa98274adPharma Surgeen2026-06-23T00:35:00.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/bio-usa-2026-china-s-biotech-rise-puts-korea-on-notice-koreabio-vp-0e4b14abe840ac58Pharma Surgeen2026-06-23T00:26:47.000Z[BIO USA 2026] China’s biotech rise puts Korea on notice: KoreaBIO VPhttps://www.pharmaradar360.com/article/ah-008-achieves-dual-regulatory-milestones-with-u-s-fda-ind-clearance-and-taiwan-bc85d2c9a1e61e7fPharma Surgeen2026-06-23T00:01:48.000ZAH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designationhttps://www.pharmaradar360.com/article/first-disease-modifying-therapy-for-nhs-use-to-delay-the-onset-of-type-1-diabete-899409ec5ea7bf35Pharma Surgeen2026-06-23T00:00:00.000ZFirst disease-modifying therapy for NHS use to delay the onset of type 1 diabetes recommendedhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-06-23T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/uct-remains-africa-s-leading-university-and-among-top-5-globally-c103ab9affe765e2Pharma Surgeen2026-06-23T00:00:00.000ZUCT remains Africa's leading university and among top 5% globallyhttps://www.pharmaradar360.com/article/author-correction-cerebellar-aging-is-spatially-heterogeneous-and-supports-cogni-c2d876b43f827100Pharma Surgeen2026-06-23T00:00:00.000ZAuthor Correction: Cerebellar aging is spatially heterogeneous and supports cognitive resilience in later lifehttps://www.pharmaradar360.com/article/shifting-the-goalposts-in-obesity-drug-development-2036ec89210e885aPharma Surgeen2026-06-23T00:00:00.000ZShifting the goalposts in obesity drug developmenthttps://www.pharmaradar360.com/article/efficient-generation-of-epitope-targeted-antibodies-with-germinal-d28af6c84e419967Pharma Surgeen2026-06-23T00:00:00.000ZEfficient generation of epitope-targeted antibodies with Germinalhttps://www.pharmaradar360.com/article/mapping-and-engineering-the-human-cell-cell-interactome-9744f21401471dcePharma Surgeen2026-06-23T00:00:00.000ZMapping and engineering the human cell–cell interactomehttps://www.pharmaradar360.com/article/retraction-note-sub-second-periodicity-in-a-fast-radio-burst-7ddee2336962ed77Pharma Surgeen2026-06-23T00:00:00.000ZRetraction Note: Sub-second periodicity in a fast radio bursthttps://www.pharmaradar360.com/article/do-not-leave-fungi-out-of-impact-assessments-b00eec718f0d84b0Pharma Surgeen2026-06-23T00:00:00.000ZDo not leave fungi out of impact assessmentshttps://www.pharmaradar360.com/article/nepal-s-new-science-ministry-must-strengthen-scientific-capacity-72eb336673f871f4Pharma Surgeen2026-06-23T00:00:00.000ZNepal’s new science ministry must strengthen scientific capacityhttps://www.pharmaradar360.com/article/the-halo-effect-how-academic-hierarchy-undermines-peer-review-and-enables-fraud-b08f0d2affc2baccPharma Surgeen2026-06-23T00:00:00.000ZThe halo effect: how academic hierarchy undermines peer review and enables fraudhttps://www.pharmaradar360.com/article/europe-as-science-superpower-what-it-will-take-to-rival-the-us-and-china-13af6e9b1208092aPharma Surgeen2026-06-23T00:00:00.000ZEurope as science superpower: what it will take to rival the US and Chinahttps://www.pharmaradar360.com/article/europe-must-seize-the-moment-to-lead-on-free-and-open-science-474b6bcdf38fb5c4Pharma Surgeen2026-06-23T00:00:00.000ZEurope must seize the moment to lead on free and open sciencehttps://www.pharmaradar360.com/article/silicon-valley-s-vision-for-global-ai-is-flawed-each-country-needs-its-own-bluep-4a58078046861b6aPharma Surgeen2026-06-23T00:00:00.000ZSilicon Valley’s vision for global AI is flawed: each country needs its own blueprinthttps://www.pharmaradar360.com/article/making-samples-one-billion-times-bigger-lets-simple-microscopes-pinpoint-amino-a-9e986e8e1d1542aaPharma Surgeen2026-06-23T00:00:00.000ZMaking samples one billion times bigger lets simple microscopes pinpoint amino acidshttps://www.pharmaradar360.com/article/a-1970s-patent-that-changed-the-course-of-commercial-biotechnology-f517d19eac1b3a31Pharma Surgeen2026-06-23T00:00:00.000ZA 1970s patent that changed the course of commercial biotechnologyhttps://www.pharmaradar360.com/article/how-should-i-respond-to-race-based-exclusion-in-my-lab-8a5a8bf1ccf383a4Pharma Surgeen2026-06-23T00:00:00.000ZHow should I respond to race-based exclusion in my lab?https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-5548a1f4d5ccf83aPharma Surgeen2026-06-23T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-dc0fa4db6f2238ccPharma Surgeen2026-06-23T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-eb0591527ab6f51aPharma Surgeen2026-06-23T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-300e6de3c6174fedPharma Surgeen2026-06-23T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-9383bbdde17e5ef6Pharma Surgeen2026-06-23T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-5a6a48e5b6e78548Pharma Surgeen2026-06-23T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-4fc62cda609126f8Pharma Surgeen2026-06-23T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-800e9eb0b6ea9f6aPharma Surgeen2026-06-23T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-5bf7e6f633f530ddPharma Surgeen2026-06-23T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-b814f126f868deccPharma Surgeen2026-06-23T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-cec7882264e9863dPharma Surgeen2026-06-23T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-a5452c41421d069bPharma Surgeen2026-06-23T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-b9a0db3121d2e5c1Pharma Surgeen2026-06-23T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-2216b4a0463327efPharma Surgeen2026-06-23T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-9bf74aaecfa046d3Pharma Surgeen2026-06-23T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-chimpanzee-research-use-form-of-c663790b02dc2fcdPharma Surgeen2026-06-23T00:00:00.000ZSubmission for OMB Review; 30-Day Comment Request; Chimpanzee Research Use Form (Office of the Director)https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-4240f569b06d1a5ePharma Surgeen2026-06-23T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification of Identity, Form FDA 3975https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pot-37adf65d0b839dbaPharma Surgeen2026-06-23T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Potential Tobacco Product Violations Reporting Formhttps://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-930d85a36215e53ePharma Surgeen2026-06-23T00:00:00.000ZPrivacy Act of 1974; System of Recordshttps://www.pharmaradar360.com/article/drug-label-update-kopa-haiku-ringworm-treatment-cream-8fa44caec5530ce6Pharma Surgeen2026-06-23T00:00:00.000ZDrug label update: Kopa Haiku Ringworm Treatment Creamhttps://www.pharmaradar360.com/article/kunskapsoversikt-visar-samband-mellan-gynekologisk-smarta-och-psykiatriska-tills-9ea10458322072eaPharma Surgeen2026-06-23T00:00:00.000ZKunskapsöversikt visar samband mellan gynekologisk smärta och psykiatriska tillståndhttps://www.pharmaradar360.com/article/fler-farliga-prostatacancerfall-hittas-med-nytt-blodtest-b11afc6c48da56a7Pharma Surgeen2026-06-23T00:00:00.000ZFler farliga prostatacancerfall hittas med nytt blodtesthttps://www.pharmaradar360.com/article/erc-anslag-till-ki-forskare-for-nya-behandlingar-mot-brostcancer-och-inflammatio-11e49fa0029102e4Pharma Surgeen2026-06-23T00:00:00.000ZERC-anslag till KI-forskare för nya behandlingar mot bröstcancer och inflammationhttps://www.pharmaradar360.com/article/cleveland-clinic-pledges-25m-to-greater-cleveland-food-bank-82fecbcecd9cbc6dPharma Surgeen2026-06-23T00:00:00.000ZCleveland Clinic Pledges $25M to Greater Cleveland Food Bankhttps://www.pharmaradar360.com/article/jama-32bdc88268f30102Pharma Surgeen2026-06-23T00:00:00.000ZJAMAhttps://www.pharmaradar360.com/article/metabolic-bariatric-surgery-declines-as-glp-1-drug-use-increases-5f3f486c0ec0eaccPharma Surgeen2026-06-23T00:00:00.000ZMetabolic Bariatric Surgery Declines as GLP-1 Drug Use Increaseshttps://www.pharmaradar360.com/article/digital-sleep-wake-cycle-metrics-may-help-predict-dementia-risk-e3e2f8011d51dcecPharma Surgeen2026-06-23T00:00:00.000ZDigital Sleep-Wake Cycle Metrics May Help Predict Dementia Riskhttps://www.pharmaradar360.com/article/single-pill-combination-therapy-for-hypertension-remains-underused-738c3f2c95e276e4Pharma Surgeen2026-06-23T00:00:00.000ZSingle-Pill Combination Therapy for Hypertension Remains Underusedhttps://www.pharmaradar360.com/article/a-new-understanding-of-hfpef-in-severe-obesity-485f26c2f63c22d4Pharma Surgeen2026-06-23T00:00:00.000ZA New Understanding of HFpEF in Severe Obesityhttps://www.pharmaradar360.com/article/how-nicotine-pouches-hook-consumers-94ae276f5901837cPharma Surgeen2026-06-23T00:00:00.000ZHow Nicotine Pouches Hook Consumershttps://www.pharmaradar360.com/article/audio-highlights-may-29-2026-f7ce8ad6ba1fb86aPharma Surgeen2026-06-23T00:00:00.000ZAudio Highlights May 29, 2026https://www.pharmaradar360.com/article/us-drug-overdose-deaths-drop-for-third-consecutive-year-5841f6e36830c6e2Pharma Surgeen2026-06-23T00:00:00.000ZUS Drug Overdose Deaths Drop for Third Consecutive Yearhttps://www.pharmaradar360.com/article/muscle-loss-grip-strength-and-walking-pace-may-be-linked-to-stroke-risk-851ccb26cdb8bff8Pharma Surgeen2026-06-23T00:00:00.000ZMuscle Loss, Grip Strength, and Walking Pace May Be Linked to Stroke Riskhttps://www.pharmaradar360.com/article/meta-analysis-ketamine-injections-rapidly-reduce-major-depressive-episode-sympto-d8079f730aee0800Pharma Surgeen2026-06-23T00:00:00.000ZMeta-Analysis: Ketamine Injections Rapidly Reduce Major Depressive Episode Symptomshttps://www.pharmaradar360.com/article/why-this-ebola-outbreak-will-be-hard-to-contain-7208f4cd000d4328Pharma Surgeen2026-06-23T00:00:00.000ZWhy This Ebola Outbreak Will Be Hard to Containhttps://www.pharmaradar360.com/article/is-there-a-doctor-on-the-ship-f7d677b7af22cffePharma Surgeen2026-06-23T00:00:00.000Z“ Is There a Doctor on the Ship?”https://www.pharmaradar360.com/article/growth-in-hospital-led-payer-integration-improving-care-or-consolidating-markets-c82dd704108b8264Pharma Surgeen2026-06-23T00:00:00.000ZGrowth in Hospital-Led Payer-Integration—Improving Care or Consolidating Markets?https://www.pharmaradar360.com/article/adult-male-hypogonadism-a-review-9ff51d7e28cf9668Pharma Surgeen2026-06-23T00:00:00.000ZAdult Male Hypogonadism: A Reviewhttps://www.pharmaradar360.com/article/hantavirus-outbreak-tests-us-after-who-withdrawal-1214c4de430e77b8Pharma Surgeen2026-06-23T00:00:00.000ZHantavirus Outbreak Tests US After WHO Withdrawalhttps://www.pharmaradar360.com/article/minimizing-adverse-effects-in-hypertension-treatment-552bcb5f465d14fbPharma Surgeen2026-06-23T00:00:00.000ZMinimizing Adverse Effects in Hypertension Treatmenthttps://www.pharmaradar360.com/article/the-influence-of-urology-on-longevity-7b54e6219bf0a4bePharma Surgeen2026-06-23T00:00:00.000ZThe Influence of Urology on Longevityhttps://www.pharmaradar360.com/article/growing-trends-in-the-payvider-model-and-us-hospital-systems-owning-health-plans-a2e630c020e4e374Pharma Surgeen2026-06-23T00:00:00.000ZGrowing Trends in the Payvider Model and US Hospital Systems Owning Health Planshttps://www.pharmaradar360.com/article/adverse-effects-and-treatment-discontinuation-of-blood-pressure-lowering-drugs-a-82448516497f1781Pharma Surgeen2026-06-23T00:00:00.000ZAdverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinationshttps://www.pharmaradar360.com/article/medical-licensing-and-state-police-power-029893c22079b72dPharma Surgeen2026-06-23T00:00:00.000ZMedical Licensing and State Police Powerhttps://www.pharmaradar360.com/article/epstein-barr-virus-associated-lymphoma-during-thiopurine-and-anti-tumour-necrosi-45a7bcebe7dc10e8Pharma Surgeen2026-06-23T00:00:00.000ZEpstein–Barr Virus-associated Lymphoma during Thiopurine and Anti-tumour Necrosis Factor Therapy: A Case Reporthttps://www.pharmaradar360.com/article/bispecific-antibody-drug-conjugates-targeting-egfr-and-lgr5-exert-potent-antitum-0d961ee471b64876Pharma Surgeen2026-06-23T00:00:00.000ZBispecific antibody-drug conjugates targeting EGFR and LGR5 exert potent antitumor activity in colorectal cancer modelshttps://www.pharmaradar360.com/article/comparative-clinical-value-of-hemogram-derived-inflammatory-indices-for-microvas-a9d67aae5f7aeb9cPharma Surgeen2026-06-23T00:00:00.000ZComparative Clinical Value of Hemogram-Derived Inflammatory Indices for Microvascular Complications in Type 2 Diabetes — a Retrospective Cross-Sectional Studyhttps://www.pharmaradar360.com/article/sequential-coexistence-of-small-lymphocytic-lymphoma-as-a-second-primary-tumor-a-c8671067ca5b9113Pharma Surgeen2026-06-23T00:00:00.000ZSequential Coexistence of Small Lymphocytic Lymphoma as a Second Primary Tumor and BCR:: ABL1-Positive Chronic Myeloid Leukemia: A Case Reporthttps://www.pharmaradar360.com/article/quality-of-recovery-qor-15-scale-from-statistical-significance-to-clinical-relev-59d691b6945ad0e4Pharma Surgeen2026-06-23T00:00:00.000ZQuality of Recovery (QoR)-15 Scale: From Statistical Significance to Clinical Relevance and Beyondhttps://www.pharmaradar360.com/article/boron-neutron-capture-therapy-for-recurrent-pediatric-sialoblastoma-the-first-cl-f2b6238e758d6d17Pharma Surgeen2026-06-23T00:00:00.000ZBoron neutron capture therapy for recurrent pediatric sialoblastoma: the first clinical experience and dosimetric considerations for skeletal safety with 4-year follow-uphttps://www.pharmaradar360.com/article/clinical-efficacy-of-piper-betle-l-nanoemulgel-as-an-adjunct-to-scaling-and-root-2afdc3fb1b250b6aPharma Surgeen2026-06-23T00:00:00.000ZClinical Efficacy of Piper betle L. Nanoemulgel as an Adjunct to Scaling and Root Planing in Chronic Periodontitis: A Randomized, Double-Blind, Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/protective-outcomes-of-high-affinity-monoclonal-antibodies-against-drug-resistan-394f5cb702a12969Pharma Surgeen2026-06-23T00:00:00.000ZProtective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strainshttps://www.pharmaradar360.com/article/evidence-like-error-and-physician-responsibility-in-retrieval-augmented-clinical-d3a5ebe9557a56baPharma Surgeen2026-06-23T00:00:00.000ZEvidence-like error and physician responsibility in retrieval-augmented clinical artificial intelligencehttps://www.pharmaradar360.com/article/clinical-and-histopathological-profile-of-breast-cancer-based-on-her2-stratifica-3865eb61b3cd6f94Pharma Surgeen2026-06-23T00:00:00.000ZClinical and Histopathological Profile of Breast Cancer Based on HER2 Stratification ASCO/CAP 2018: Analysis of HER2-Positive, Negative, Low, and Ultralowhttps://www.pharmaradar360.com/article/garengeot-hernia-preperitoneal-approach-in-the-context-of-strangulation-case-rep-23e74bd2a9a1ad57Pharma Surgeen2026-06-23T00:00:00.000ZGarengeot hernia: preperitoneal approach in the context of strangulation, case reporthttps://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-of-the-calcaneo-stop-procedure-for-symptomati-c138f1e181ede4bcPharma Surgeen2026-06-23T00:00:00.000ZClinical and Radiographic Outcomes of the Calcaneo-stop Procedure for Symptomatic Flexible Flatfoot in Adolescents: A Retrospective Cohort Study of 160 Feethttps://www.pharmaradar360.com/article/construction-and-validation-of-a-model-integrating-radiomics-and-clinical-featur-4b2261fd0533e19aPharma Surgeen2026-06-23T00:00:00.000ZConstruction and Validation of a Model Integrating Radiomics and Clinical Features for Predicting Microsatellite Status in Colorectal Cancerhttps://www.pharmaradar360.com/article/does-the-use-of-liposomal-bupivacaine-in-hip-fracture-surgery-have-any-advantage-f6982e4c584955f5Pharma Surgeen2026-06-23T00:00:00.000ZDoes the Use of Liposomal Bupivacaine in Hip Fracture Surgery Have Any Advantage Over Conventional Analgesia for Postoperative Pain Control?https://www.pharmaradar360.com/article/clinical-laboratory-sciences-in-the-kingdom-of-saudi-arabia-history-education-an-164359e74bfae1c0Pharma Surgeen2026-06-23T00:00:00.000ZClinical Laboratory Sciences in the Kingdom of Saudi Arabia: History, Education, and Current Landscapehttps://www.pharmaradar360.com/article/visualization-exploration-and-application-effect-of-drug-configuration-process-b-f7e7b12f823b74ccPharma Surgeen2026-06-23T00:00:00.000ZVisualization Exploration and Application Effect of Drug Configuration Process Based on Daytime Chemotherapy Interaction Design Information Systemhttps://www.pharmaradar360.com/article/retraction-note-clinical-significance-of-airway-mucus-hypersecretion-in-chronic-72cf7f77ea51ea1cPharma Surgeen2026-06-23T00:00:00.000ZRetraction note: Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary diseasehttps://www.pharmaradar360.com/article/early-procalcitonin-kinetics-and-28-day-mortality-in-critical-illness-a-pragmati-02c9af63363a52b3Pharma Surgeen2026-06-23T00:00:00.000ZEarly procalcitonin kinetics and 28-day mortality in critical illness: a pragmatic Bayesian modelling approachhttps://www.pharmaradar360.com/article/national-comparability-and-inter-laboratory-performance-of-cortisol-immunoassays-737d636594b4166aPharma Surgeen2026-06-23T00:00:00.000ZNational comparability and inter-laboratory performance of cortisol immunoassays and LC-MS/MS methodshttps://www.pharmaradar360.com/article/enhancing-the-norepinephrine-transporter-expression-and-lt-sup-gt-211-lt-sup-gt-b4be4d97fb686b5cPharma Surgeen2026-06-23T00:00:00.000ZEnhancing the Norepinephrine Transporter Expression and [<sup>211</sup>At]MABG Uptake with Vorinostat Preloading in the Pheochromocytoma Modelhttps://www.pharmaradar360.com/article/lipopolysaccharide-induced-changes-in-facial-expression-and-orofacial-movement-i-26681344f2d0a333Pharma Surgeen2026-06-23T00:00:00.000ZLipopolysaccharide-Induced Changes in Facial Expression and Orofacial Movement in Micehttps://www.pharmaradar360.com/article/clinical-electrophysiological-and-neuropathological-features-of-peripheral-neuro-a5078c8d6d410f32Pharma Surgeen2026-06-23T00:00:00.000ZClinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorderhttps://www.pharmaradar360.com/article/clinical-reasoning-a-32-year-old-woman-with-progressive-vision-loss-and-confusio-191667e5dc6f22e5Pharma Surgeen2026-06-23T00:00:00.000ZClinical Reasoning: A 32-Year-Old Woman With Progressive Vision Loss and Confusionhttps://www.pharmaradar360.com/article/accuracy-of-final-canine-retraction-with-and-without-a-palatal-power-arm-using-i-65ed507e492c0c86Pharma Surgeen2026-06-23T00:00:00.000ZAccuracy of final canine retraction with and without a palatal power arm using in-house clear aligners: a randomized clinical trialhttps://www.pharmaradar360.com/article/clinical-outcomes-and-parental-of-two-stainless-steel-crown-systems-in-pediatric-e4dc2189d250e2d7Pharma Surgeen2026-06-23T00:00:00.000ZClinical outcomes and parental of two stainless steel crown systems in pediatric patients: a retrospective observational cohort studyhttps://www.pharmaradar360.com/article/development-and-validation-of-an-interpretable-machine-learning-model-for-early-5932586e500edad2Pharma Surgeen2026-06-23T00:00:00.000ZDevelopment and validation of an interpretable machine learning model for early hospital-based differentiation of chikungunya and dengue fever using routine clinical datahttps://www.pharmaradar360.com/article/low-dose-intrathecal-morphine-versus-intrathecal-fentanyl-for-post-caesarean-ana-8257ba3ef8bb526fPharma Surgeen2026-06-23T00:00:00.000ZLow-dose intrathecal morphine versus intrathecal fentanyl for post-caesarean analgesia in a resource-constrained setting: a pragmatic randomised trialhttps://www.pharmaradar360.com/article/beyond-primary-patents-strategic-intellectual-property-frameworks-for-sustained-51b56eac911ff5b6Pharma Surgeen2026-06-23T00:00:00.000ZBeyond primary patents: Strategic intellectual property frameworks for sustained pharmaceutical market dominance in US & EUhttps://www.pharmaradar360.com/article/midterm-clinical-and-echocardiographic-outcomes-after-transcatheter-aortic-valve-e87fae0a1af7928fPharma Surgeen2026-06-23T00:00:00.000ZMidterm Clinical and Echocardiographic Outcomes After Transcatheter Aortic Valve Replacement in Patients With Severe Bicuspid Aortic Valve Stenosishttps://www.pharmaradar360.com/article/a-slow-regular-rhythm-after-tavr-a-clinical-reasoning-exercise-5b37a5ccbaab2da6Pharma Surgeen2026-06-23T00:00:00.000ZA Slow Regular Rhythm After TAVR: A Clinical Reasoning Exercisehttps://www.pharmaradar360.com/article/angiotensin-receptor-neprilysin-inhibitor-in-heart-failure-with-preserved-ejecti-eba015785baed931Pharma Surgeen2026-06-23T00:00:00.000ZAngiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trialhttps://www.pharmaradar360.com/article/laroprovstat-the-first-oral-small-molecule-pcsk9-inhibitor-for-the-treatment-of-5ab6a734084092d7Pharma Surgeen2026-06-23T00:00:00.000ZLaroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patientshttps://www.pharmaradar360.com/article/active-and-passive-knitting-rhythm-on-eeg-909cd8ff72f7e7bePharma Surgeen2026-06-23T00:00:00.000ZActive and Passive Knitting Rhythm on EEGhttps://www.pharmaradar360.com/article/anatomy-and-structural-connectivity-of-the-opercula-43c308627870f779Pharma Surgeen2026-06-23T00:00:00.000ZAnatomy and Structural Connectivity of the Operculahttps://www.pharmaradar360.com/article/navigating-hantavirus-risk-in-transplantation-implications-for-clinical-practice-9678c597609254d1Pharma Surgeen2026-06-23T00:00:00.000ZNavigating Hantavirus Risk in Transplantation: Implications for Clinical Practicehttps://www.pharmaradar360.com/article/effect-of-a-liquid-crystal-vein-locator-on-intravenous-catheterization-in-young-43e4ca188cb0700dPharma Surgeen2026-06-23T00:00:00.000ZEffect of a liquid crystal vein locator on intravenous catheterization in young children: a randomized trialhttps://www.pharmaradar360.com/article/auditory-involvement-in-inflammatory-bowel-disease-clinical-predictors-and-progn-7d25a828ef951125Pharma Surgeen2026-06-23T00:00:00.000ZAuditory Involvement in Inflammatory Bowel Disease: Clinical Predictors and Prognostic Implicationshttps://www.pharmaradar360.com/article/home-based-trimodal-prehabilitation-before-lung-resection-a-single-center-random-20766de38d39e2eePharma Surgeen2026-06-23T00:00:00.000ZHome-based trimodal prehabilitation before lung resection: a single-center randomized controlled trialhttps://www.pharmaradar360.com/article/a-commentary-on-clinical-outcomes-of-norepinephrine-phenylephrine-vs-norepinephr-c82a0742df1a61f7Pharma Surgeen2026-06-23T00:00:00.000ZA commentary on “Clinical outcomes of norepinephrine-phenylephrine vs. norepinephrine-vasopressin in septic shock: a retrospective cohort study”https://www.pharmaradar360.com/article/excerpts-from-march-april-2025-issue-of-acce-news-0e93327c8e86f993Pharma Surgeen2026-06-23T00:00:00.000ZExcerpts from March-April 2025 Issue of ACCE Newshttps://www.pharmaradar360.com/article/risk-management-7-safety-service-contract-management-ad357e6c88415d57Pharma Surgeen2026-06-23T00:00:00.000ZRisk Management 7 Safety Service Contract Managementhttps://www.pharmaradar360.com/article/doctronic-raises-40-billion-in-series-b-funding-4553886b441da389Pharma Surgeen2026-06-23T00:00:00.000ZDoctronic Raises $40 Billion in Series B Fundinghttps://www.pharmaradar360.com/article/osu-chs-tops-us-news-rankings-in-serving-health-care-shortage-areas-3d2a35bfa6f51abcPharma Surgeen2026-06-23T00:00:00.000ZOSU-CHS Tops US News Rankings in Serving Health Care Shortage Areashttps://www.pharmaradar360.com/article/circa-scientific-inc-appoints-medtech-executive-vafa-jamali-to-board-of-director-781a2e622a0e39caPharma Surgeen2026-06-23T00:00:00.000ZCIRCA Scientific, Inc. Appoints MedTech Executive Vafa Jamali to Board of Directorshttps://www.pharmaradar360.com/article/the-qsmr-shift-why-htm-is-the-new-frontline-of-hospital-risk-bef3bc8bb3c850aePharma Surgeen2026-06-23T00:00:00.000ZThe QSMR Shift: Why HTM Is the New Frontline of Hospital Riskhttps://www.pharmaradar360.com/article/reasons-for-different-laboratory-results-in-northern-sudan-case-study-in-merowe-3e9a6fa60b9006abPharma Surgeen2026-06-23T00:00:00.000ZReasons for Different Laboratory Results in Northern Sudan (Case Study in Merowe)https://www.pharmaradar360.com/article/transfer-learning-for-low-resource-genomic-mutation-detection-84b7c8196cb3e15bPharma Surgeen2026-06-23T00:00:00.000ZTransfer Learning for Low-resource Genomic Mutation Detectionhttps://www.pharmaradar360.com/article/response-to-panteghini-about-analytical-performance-specifications-for-immunosup-4e8f23e0fdb2702cPharma Surgeen2026-06-23T00:00:00.000ZResponse to Panteghini “About Analytical Performance Specifications for Immunosuppressive Drug Measurements”https://www.pharmaradar360.com/article/postsurgical-care-in-nail-surgery-recommendations-based-on-evidence-and-clinical-182f28ccfe2ce5f6Pharma Surgeen2026-06-23T00:00:00.000ZPostsurgical Care in Nail Surgery: Recommendations Based on Evidence and Clinical Experiencehttps://www.pharmaradar360.com/article/are-age-based-cutoffs-for-tha-logically-consistent-881f6dfe5985adb0Pharma Surgeen2026-06-23T00:00:00.000ZAre Age-based Cutoffs for THA Logically Consistent?https://www.pharmaradar360.com/article/corr-insights-are-lgbtq-allyship-symbols-associated-with-patient-trust-in-the-or-13e925a5551b5e3aPharma Surgeen2026-06-23T00:00:00.000ZCORR Insights®: Are LGBTQ+ Allyship Symbols Associated With Patient Trust in the Orthopaedic Surgeon? A Dual Cohort Surveyhttps://www.pharmaradar360.com/article/preoperative-distal-motor-latency-testing-and-long-term-outcomes-in-combined-lum-0bdb8751df8f878cPharma Surgeen2026-06-23T00:00:00.000ZPreoperative Distal Motor Latency Testing and Long-Term Outcomes in Combined Lumbar Spinal Stenosishttps://www.pharmaradar360.com/article/clinical-accuracy-and-applications-of-large-language-models-in-pediatric-orthope-64467496eb7263b3Pharma Surgeen2026-06-23T00:00:00.000ZClinical accuracy and applications of large language models in pediatric orthopedics: a systematic reviewhttps://www.pharmaradar360.com/article/comparative-10-year-performance-of-mammography-artificial-intelligence-polygenic-d1287b6b520cdd2cPharma Surgeen2026-06-23T00:00:00.000ZComparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bankhttps://www.pharmaradar360.com/article/indications-protocols-and-interpretation-of-cardiovascular-imaging-for-the-evalu-54eef456929eb5f4Pharma Surgeen2026-06-23T00:00:00.000ZIndications, protocols, and interpretation of cardiovascular imaging for the evaluation and management of athletes: a clinical consensus statement of the European Association of Preventive Cardiology (EAPC) and the European Association of Cardiovascular Imaging (EACVI) of the European Society of Carhttps://www.pharmaradar360.com/article/heart-failure-inequality-and-the-decades-before-admission-2f3e36c67478b065Pharma Surgeen2026-06-23T00:00:00.000ZHeart failure, inequality, and the decades before admissionhttps://www.pharmaradar360.com/article/generating-evidence-using-electronic-alerts-during-routine-care-a-fully-automate-939392cabdd1837fPharma Surgeen2026-06-23T00:00:00.000ZGenerating evidence using electronic alerts during routine care: a fully automated randomised controlled trial of oral fluid restriction in acute heart failure (THIRST Alert Trial)https://www.pharmaradar360.com/article/indications-protocols-and-interpretation-of-cardiovascular-imaging-for-the-evalu-a0680ca0fe9ac766Pharma Surgeen2026-06-23T00:00:00.000ZIndications, protocols, and interpretation of cardiovascular imaging for the evaluation and management of athletes: a clinical consensus statement of the European Association of Preventive Cardiology (EAPC) and the European Association of Cardiovascular Imaging (EACVI) of the ESC: Part 1—Exercise imhttps://www.pharmaradar360.com/article/aptamer-based-biosensing-strategies-for-influenza-virus-detection-a-systematic-a-d2bdd03c4fecb470Pharma Surgeen2026-06-23T00:00:00.000ZAptamer-based biosensing strategies for influenza virus detection: a systematic and critical review of electrochemical and optical platformshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-infigratinib-in-patients-with-refractory-advanced-gastric-33d7f14c42dc93a7Pharma Surgeen2026-06-23T00:00:00.000ZEfficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trialhttps://www.pharmaradar360.com/article/bridging-to-surgery-versus-palliation-in-malignant-colorectal-obstruction-compli-55fa6d82de65c728Pharma Surgeen2026-06-23T00:00:00.000ZBridging to surgery versus palliation in malignant colorectal obstruction: complication risks and mediation by clinical successhttps://www.pharmaradar360.com/article/european-society-of-clinical-pharmacy-bridging-gaps-clinical-pharmacy-in-the-dig-347c7274835be0c4Pharma Surgeen2026-06-23T00:00:00.000ZEuropean Society of Clinical Pharmacy: bridging gaps—clinical pharmacy in the digital transition of carehttps://www.pharmaradar360.com/article/from-relapse-to-survival-real-world-clinical-impact-of-a-multimodal-approach-in-959cfed93bd0cc14Pharma Surgeen2026-06-23T00:00:00.000ZFrom relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastomahttps://www.pharmaradar360.com/article/real-world-evidence-on-jak-inhibitors-in-rheumatology-practice-comparative-safet-a840c5bb1bf85506Pharma Surgeen2026-06-23T00:00:00.000ZReal-world evidence on JAK inhibitors in rheumatology practice: comparative safety, efficacy, and outcomes between JAK inhibitorshttps://www.pharmaradar360.com/article/promoting-the-utilization-of-rheumatologic-musculoskeletal-anatomy-a-50-year-tra-ff71c130251a5a02Pharma Surgeen2026-06-23T00:00:00.000ZPromoting the utilization of rheumatologic musculoskeletal anatomy: a 50-year travel loghttps://www.pharmaradar360.com/article/a-proof-of-concept-for-a-novel-mandibular-dental-implant-model-in-mice-b279740ffe67bcb1Pharma Surgeen2026-06-23T00:00:00.000ZA proof-of-concept for a novel mandibular dental implant model in micehttps://www.pharmaradar360.com/article/mechanisms-of-weight-gain-associated-with-valproic-acid-a-scoping-review-4427fd17a896fb69Pharma Surgeen2026-06-23T00:00:00.000ZMechanisms of weight gain associated with valproic acid: a scoping reviewhttps://www.pharmaradar360.com/article/a-living-biobank-of-sarcoma-patient-derived-cell-cultures-reveals-multi-omic-and-8a20af4409b4570fPharma Surgeen2026-06-23T00:00:00.000ZA living biobank of sarcoma patient‐derived cell cultures reveals multi‐omic and functional insights that capture disease heterogeneityhttps://www.pharmaradar360.com/article/diagnostic-value-and-treatment-responsiveness-of-ultrasound-features-in-correlat-96db68cb262131fcPharma Surgeen2026-06-23T00:00:00.000ZDiagnostic Value and Treatment Responsiveness of Ultrasound Features in correlation with clinical findings in Early Peripheral Spondyloarthritishttps://www.pharmaradar360.com/article/nct07663513-iparomlimab-and-tovorilimab-ql1706-combined-with-bevacizumab-and-che-91f9a619ff2542bfPharma Surgeen2026-06-23T00:00:00.000ZNCT07663513: Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancerhttps://www.pharmaradar360.com/article/nct07662720-a-phase-ii-trial-for-mor-antagonism-with-axelopran-to-enhance-immuno-6d9404801e96cad1Pharma Surgeen2026-06-23T00:00:00.000ZNCT07662720: A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancerhttps://www.pharmaradar360.com/article/nct07662369-cd45ra-depleted-dli-for-the-treatment-of-refractory-persistent-viral-7275833145f72f80Pharma Surgeen2026-06-23T00:00:00.000ZNCT07662369: CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantationhttps://www.pharmaradar360.com/article/nct07658729-effects-of-music-therapy-in-chronic-neck-pain-4d5c73290f5b7c00Pharma Surgeen2026-06-23T00:00:00.000ZNCT07658729: Effects of Music Therapy in Chronic Neck Painhttps://www.pharmaradar360.com/article/nct07602296-evaluating-how-red-light-therapy-applied-to-the-head-affects-symptom-12631b675ab0433aPharma Surgeen2026-06-23T00:00:00.000ZNCT07602296: Evaluating How Red-light Therapy Applied to the Head Affects Symptoms, Daily Life, and Brain Activity in People With Dementia With Lewy Bodieshttps://www.pharmaradar360.com/article/nct07599176-partial-stem-cell-transplant-for-sickle-cell-disease-from-matched-do-d6f5336760d056f1Pharma Surgeen2026-06-23T00:00:00.000ZNCT07599176: Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donorshttps://www.pharmaradar360.com/article/nct07539311-study-to-assess-the-efficacy-and-safety-of-rina-s-in-participants-wi-17280bfeb0b28b57Pharma Surgeen2026-06-23T00:00:00.000ZNCT07539311: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancershttps://www.pharmaradar360.com/article/nct07519772-a-clinical-study-of-mk-1045-in-people-with-non-hodgkin-lymphoma-mk-1-a50ac56f09684b1dPharma Surgeen2026-06-23T00:00:00.000ZNCT07519772: A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)https://www.pharmaradar360.com/article/nct07376785-can-smartphones-listen-to-your-heart-a-performance-study-on-detectin-1b65f23e69ececdbPharma Surgeen2026-06-23T00:00:00.000ZNCT07376785: Can Smartphones Listen to Your Heart? A Performance Study on Detecting Inborn Heart Diseases in Your Heart Soundshttps://www.pharmaradar360.com/article/nct07357831-a-phase-iii-trial-to-evaluate-the-efficacy-and-safety-of-mc2-01-crea-4829f5d92fc7a1e3Pharma Surgeen2026-06-23T00:00:00.000ZNCT07357831: A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjectshttps://www.pharmaradar360.com/article/nct07290257-long-term-low-intervention-safety-and-clinical-outcomes-clinical-stu-ca31c8eb093d01a3Pharma Surgeen2026-06-23T00:00:00.000ZNCT07290257: Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)https://www.pharmaradar360.com/article/nct07287540-anti-inflammatory-nutrition-on-the-outcomes-of-non-surgical-periodon-c32ffb70a8cf6cf9Pharma Surgeen2026-06-23T00:00:00.000ZNCT07287540: Anti-inflammatory Nutrition on the Outcomes of Non-surgical Periodontal Therapyhttps://www.pharmaradar360.com/article/nct07195734-testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-the-u-eaef4d5ec3a3e699Pharma Surgeen2026-06-23T00:00:00.000ZNCT07195734: Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancerhttps://www.pharmaradar360.com/article/nct07157774-assessing-the-impact-of-muvalaplin-on-major-cardiovascular-events-in-0365f0b120f4423cPharma Surgeen2026-06-23T00:00:00.000ZNCT07157774: Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)https://www.pharmaradar360.com/article/nct07125430-shock-wave-treatment-in-patients-with-knee-osteoarthritis-ff924be33b7facecPharma Surgeen2026-06-23T00:00:00.000ZNCT07125430: Shock Wave Treatment in Patients With Knee Osteoarthritishttps://www.pharmaradar360.com/article/nct07102524-intrathecal-gene-therapy-for-slc13a5-citrate-transporter-disorder-f0ccb7294634825dPharma Surgeen2026-06-23T00:00:00.000ZNCT07102524: Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorderhttps://www.pharmaradar360.com/article/nct07018323-a-study-to-assess-the-efficacy-safety-and-tolerability-of-imvt-1402-f149bff035a715c2Pharma Surgeen2026-06-23T00:00:00.000ZNCT07018323: A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Diseasehttps://www.pharmaradar360.com/article/nct06968806-study-on-ketorolac-for-improving-outcomes-and-prognosis-in-patients-aa833c73db263891Pharma Surgeen2026-06-23T00:00:00.000ZNCT06968806: Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissectionhttps://www.pharmaradar360.com/article/nct06953960-a-study-to-assess-adverse-events-and-change-in-disease-activity-of-o-c2f79e6dd1bdf31aPharma Surgeen2026-06-23T00:00:00.000ZNCT06953960: A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)https://www.pharmaradar360.com/article/nct06940141-rademikibart-add-on-treatment-of-an-acute-asthma-exacerbation-seabre-851ef98496416e60Pharma Surgeen2026-06-23T00:00:00.000ZNCT06940141: Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)https://www.pharmaradar360.com/article/nct06910293-whole-brain-dynamics-in-the-natural-menstrual-cycle-vs-an-ovarian-st-050dd6510d64a71cPharma Surgeen2026-06-23T00:00:00.000ZNCT06910293: Whole-Brain Dynamics in the Natural Menstrual Cycle vs. an Ovarian Stimulated Cycle: Impact of Hormonal Fluctuations on Healthy Women Undergoing Ovarian Stimulationhttps://www.pharmaradar360.com/article/nct06744283-experience-and-management-of-cancer-screening-related-anxiety-in-fan-4217b728233e0099Pharma Surgeen2026-06-23T00:00:00.000ZNCT06744283: Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemiahttps://www.pharmaradar360.com/article/nct06596694-study-of-patritumab-deruxtecan-in-participants-with-gastrointestinal-73a4841de8c7ca86Pharma Surgeen2026-06-23T00:00:00.000ZNCT06596694: Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)https://www.pharmaradar360.com/article/nct06581432-beamion-pantumor-1-a-study-to-test-whether-zongertinib-helps-people-8be8ee03c6cb9724Pharma Surgeen2026-06-23T00:00:00.000ZNCT06581432: Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterationshttps://www.pharmaradar360.com/article/nct06435910-engineered-dendritic-cell-vaccines-for-multiple-myeloma-9a5d61431549227cPharma Surgeen2026-06-23T00:00:00.000ZNCT06435910: Engineered Dendritic Cell Vaccines for Multiple Myelomahttps://www.pharmaradar360.com/article/nct06180746-study-of-the-conditions-of-the-effects-of-health-mediation-on-unders-95a59f24e4d17f43Pharma Surgeen2026-06-23T00:00:00.000ZNCT06180746: Study of the Conditions of the Effects of Health Mediation on Underserved Populationhttps://www.pharmaradar360.com/article/nct06132113-dareontm-7-a-study-to-test-how-well-different-doses-of-bi-764532-in-5628c29cc964e8f7Pharma Surgeen2026-06-23T00:00:00.000ZNCT06132113: DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancershttps://www.pharmaradar360.com/article/nct05829655-measuring-acute-drug-demand-in-humans-94c453913eebf7d6Pharma Surgeen2026-06-23T00:00:00.000ZNCT05829655: Measuring Acute Drug Demand in Humanshttps://www.pharmaradar360.com/article/nct05684965-xtx301-in-patients-with-advanced-solid-tumors-b681bb9719fb093fPharma Surgeen2026-06-23T00:00:00.000ZNCT05684965: XTX301 in Patients With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct05437341-psma-cd70-bi-specific-car-t-cell-therapy-bf494d568cc2b4b2Pharma Surgeen2026-06-23T00:00:00.000ZNCT05437341: PSMA/CD70 Bi-specific CAR-T Cell Therapyhttps://www.pharmaradar360.com/article/nct05368207-pembrolizumab-in-small-cell-carcinoma-of-ovary-hypercalcemic-type-pa-a516bc7cd0e17c25Pharma Surgeen2026-06-23T00:00:00.000ZNCT05368207: Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patienthttps://www.pharmaradar360.com/article/nct05189223-a-brief-values-intervention-to-support-veterans-in-early-buprenorphi-29ceef5a86709d20Pharma Surgeen2026-06-23T00:00:00.000ZNCT05189223: A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatmenthttps://www.pharmaradar360.com/article/nct04609046-testing-the-addition-of-lenalidomide-and-nivolumab-to-the-usual-trea-7f50f948c51ec8edPharma Surgeen2026-06-23T00:00:00.000ZNCT04609046: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphomahttps://www.pharmaradar360.com/article/nct04181827-a-study-comparing-jnj-68284528-a-car-t-therapy-directed-against-b-ce-76be6951b93e0400Pharma Surgeen2026-06-23T00:00:00.000ZNCT04181827: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct04010877-multiple-car-t-cell-therapy-targeting-aml-fd18700a4dd99196Pharma Surgeen2026-06-23T00:00:00.000ZNCT04010877: Multiple CAR-T Cell Therapy Targeting AMLhttps://www.pharmaradar360.com/article/nct03586661-niraparib-and-copanlisib-in-treating-patients-with-recurrent-endomet-db077523faac9e7fPharma Surgeen2026-06-23T00:00:00.000ZNCT03586661: Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancerhttps://www.pharmaradar360.com/article/nct03194906-memantine-for-prevention-of-cognitive-late-effects-in-pediatric-pati-91323c669a2b7beePharma Surgeen2026-06-23T00:00:00.000ZNCT03194906: Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumorshttps://www.pharmaradar360.com/article/nct01371630-inotuzumab-ozogamicin-and-combination-chemotherapy-in-treating-patie-fd01d55795bf1cd5Pharma Surgeen2026-06-23T00:00:00.000ZNCT01371630: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/nct00520975-bevacizumab-in-treating-patients-with-metastatic-breast-cancer-that-d10e048ec29a2e6bPharma Surgeen2026-06-23T00:00:00.000ZNCT00520975: Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUhttps://www.pharmaradar360.com/article/nct00231400-pompe-disease-registry-protocol-489eefcfe7a3f241Pharma Surgeen2026-06-23T00:00:00.000ZNCT00231400: Pompe Disease Registry Protocolhttps://www.pharmaradar360.com/article/how-teva-s-ecopipam-tourette-nda-and-austedo-data-will-impact-teva-pharmaceutica-7ef5373b8c703795Pharma Surgeen2026-06-22T23:41:56.000ZHow Teva’s Ecopipam Tourette NDA and AUSTEDO Data Will Impact Teva Pharmaceutical Industries (TEVA) Investorshttps://www.pharmaradar360.com/article/did-new-voxzogo-and-bmn-333-data-just-shift-biomarin-pharmaceutical-s-bmrn-inves-c70a1d02c6358ffaPharma Surgeen2026-06-22T23:41:56.000ZDid New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's (BMRN) Investment Narrative?https://www.pharmaradar360.com/article/majority-of-americans-value-women-s-safety-over-ease-of-abortion-drug-access-5ae088def45bbd22Pharma Surgeen2026-06-22T23:17:02.000ZMajority of Americans Value Women’s Safety over Ease of Abortion Drug Accesshttps://www.pharmaradar360.com/article/health-brief-fda-signals-reset-in-drug-reviews-03da7d5f869b1c43Pharma Surgeen2026-06-22T23:07:33.000ZHealth Brief: FDA signals reset in drug reviewshttps://www.pharmaradar360.com/article/nuvectis-announces-strategic-portfolio-expansion-via-license-agreement-for-ex-ch-9b9cb853baff095cPharma Surgeen2026-06-22T22:18:52.000ZNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compoundshttps://www.pharmaradar360.com/article/el-investigador-del-cnic-florian-weinberger-obtiene-una-erc-advanced-grant-para-cf29422fc3a8880bPharma Surgeen2026-06-22T22:00:00.000ZEl investigador del CNIC Florian Weinberger obtiene una ERC Advanced Grant para el proyecto CARDIOSWITCHhttps://www.pharmaradar360.com/article/fda-launches-pilot-to-speed-drug-testing-as-china-surges-in-biotech-race-636d335d2f832c3bPharma Surgeen2026-06-22T21:54:08.000ZFDA launches pilot to speed drug testing as China surges in biotech racehttps://www.pharmaradar360.com/article/ups-adds-27-cold-transfer-facilities-for-pharmaceutical-shipping-75cdcad87c620595Pharma Surgeen2026-06-22T21:53:36.000ZUPS adds 27 cold transfer facilities for pharmaceutical shippinghttps://www.pharmaradar360.com/article/chart-master-is-it-time-to-buy-biotech-3a4b344cd466e810Pharma Surgeen2026-06-22T21:49:00.000ZChart Master: Is it time to buy biotech?https://www.pharmaradar360.com/article/montana-voters-support-cigarette-tax-increase-to-prevent-addiction-and-save-live-b65bd59ff26f63a2Pharma Surgeen2026-06-22T21:29:00.000ZMontana voters support cigarette tax increase to prevent addiction and save liveshttps://www.pharmaradar360.com/article/serratiopeptidase-pharmaceutical-enzyme-market-growth-forecast-to-2035-bioproces-2e7031a9f6270265Pharma Surgeen2026-06-22T21:26:25.000ZSerratiopeptidase Pharmaceutical Enzyme Market Growth Forecast to 2035: Bioprocessing and Therapeutic Demand Accelerate - News and Statisticshttps://www.pharmaradar360.com/article/machine-learning-based-covariate-selection-for-population-pharmacokinetic-modeli-b686a10122dde4d9Pharma Surgeen2026-06-22T21:24:44.000ZMachine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling